Department of Nuclear Medicine, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Department of Nuclear Medicine, the Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
Endocr Pract. 2022 Jun;28(6):586-592. doi: 10.1016/j.eprac.2022.03.005. Epub 2022 Mar 15.
The study aimed to investigate whether urinary iodine concentration (UIC) and urinary iodine to creatinine ratio (UICR) measurements can act as markers for the curative effect of radioactive iodine (RAI) therapy.
A total of 337 patients who underwent RAI therapy between May 2018 and March 2020 were recruited. According to the levels of UIC or UICR, patients were divided into 6 groups: group A, UIC levels of <100 μg/L; group B, UIC levels ranging from 100 to 200 μg/L; group C, UIC levels of ≥200 μg/L; group D, UICR levels of <100 μg/g; group E, UICR levels ranging from 100 to 200 μg/g; and group F, UICR levels of ≥200 μg/g. Treatment and follow-up were defined according to the criteria used in the 2015 ATA guidelines.
When dividing the 337 patients into 3 groups according to UIC levels, 50.7%, 22.6%, and 26.7% of patients were in the A, B, and C groups, respectively. Based on the UICR levels, 58.1%, 29.4%, and 12.5% of patients were in the D, E, and F groups, respectively. There was a significant positive correlation between UIC and UICR levels and iodine-131 uptake rates (P < .001). The excellent response rate was not significantly different between the UIC groups (P = .997) and the UICR groups (P = .634). In logistic regression analysis, UIC and UICR levels were not confirmed to be independent factors predicting the excellent response status, but an age of ≥55 years (OR = 0.373; P = .007) and Tg levels of ≥10 ng/mL (OR = 18.972; P = .001) were confirmed to be independent factors predicting the excellent response status at the end of follow-up.
The UIC or UICR levels before RAI therapy did not compromise the therapeutic response to iodine-131.
本研究旨在探讨尿碘浓度（UIC）和尿碘/肌酐比值（UICR）测量值是否可作为放射性碘（RAI）治疗疗效的标志物。
共纳入 2018 年 5 月至 2020 年 3 月期间接受 RAI 治疗的 337 例患者。根据 UIC 或 UICR 水平，患者分为 6 组：A 组，UIC 水平＜100μg/L；B 组，UIC 水平为 100～200μg/L；C 组，UIC 水平≥200μg/L；D 组，UICR 水平＜100μg/g；E 组，UICR 水平为 100～200μg/g；F 组，UICR 水平≥200μg/g。根据 2015 年 ATA 指南中的标准对治疗和随访进行定义。
根据 UIC 水平将 337 例患者分为 3 组，A、B 和 C 组患者分别占 50.7%、22.6%和 26.7%。根据 UICR 水平，D、E 和 F 组患者分别占 58.1%、29.4%和 12.5%。UIC 和 UICR 水平与碘-131 摄取率之间存在显著正相关（P＜0.001）。UIC 组（P=0.997）和 UICR 组（P=0.634）之间的优秀反应率无显著差异。Logistic 回归分析显示，UIC 和 UICR 水平未被确认为预测优秀反应状态的独立因素，但年龄≥55 岁（OR=0.373；P=0.007）和 Tg 水平≥10ng/mL（OR=18.972；P=0.001）被确认为预测随访结束时优秀反应状态的独立因素。
RAI 治疗前的 UIC 或 UICR 水平并不影响碘-131 的治疗反应。
